Evidence map›Paper›PMID 40569674›Full record

ArticleJCI insight2025

Spatial proteomics and transcriptomics reveal early immune cell organization in pancreatic intraepithelial neoplasia.

Melissa R Lyman, Jacob T Mitchell, Sidharth Raghavan, Luciane T Kagohara, Amanda L Huff, Saurav D Haldar, Sarah M Shin, Samantha Guinn, Benjamin Barrett, Gabriella Longway and 24 more

Abstract read
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Melissa R LymanDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Jacob T MitchellDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Sidharth RaghavanDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Luciane T KagoharaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Amanda L HuffDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Saurav D HaldarDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Sarah M ShinDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Samantha GuinnDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Benjamin BarrettDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Gabriella LongwayDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Alexei HernandezDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Erin M CoyneDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Xuan YuanDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Lalitya AndalooriDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Jiaying LaiComputational Medicine.
Yun Zhou LiuComputational Medicine.
Rachel KarchinComputational Medicine.
Anuj GuptaComputational Medicine.
Ashley L KiemenDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
André ForjazDepartment of Chemical and Biomolecular Engineering.
Denis WirtzDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Pei-Hsun WuDepartment of Chemical and Biomolecular Engineering.
Atul DeshpandeDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Jae W LeeDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Todd D ArmstrongDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Nilofer S AzadDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Jacquelyn W ZimmermanDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Laura D WoodDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Robert A AndersConvergence Institute.
Elizabeth D ThompsonDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Elizabeth M JaffeeDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Elana J FertigDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Won Jin HoDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.
Neeha ZaidiDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center.

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI THOMPSON, ELIZABETH D · 1993 to 2022
$54.6M
TRANS NETWORK PROJECTSU54CA143868 · NCI · JOHNS HOPKINS UNIVERSITY · PI WIRTZ, DENIS · 2009 to 2013
$13.7M
Transforming Human Pancreatic Cancer Into An Immunologic DiseaseP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · PI FERTIG, ELANA · 2021 to 2025
$12.7M
Predoctoral Training Program in Human GeneticsT32GM007814 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 1985 to 2021
$10.6M
Tech Core 2U54CA268083 · NCI · JOHNS HOPKINS UNIVERSITY · PI Denis Wirtz, Laura DeLong Wood · 2022 to 2026
$10.2M
Tumor Microenvironment Crosstalk Drives Early Lesions in Pancreatic CancerU54CA274371 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Elana Fertig · 2022 to 2026
$9.5M
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical TrialR01CA197296 · NCI · JOHNS HOPKINS UNIVERSITY · PI William Reece Burns, Eric Christenson · 2015 to 2026
$5.7M
Mutant KRAS targeted vaccines for the interception of pancreatic cancer developmentR37CA292056 · NCI · JOHNS HOPKINS UNIVERSITY · PI Neeha Zaidi · 2024 to 2026
$2.0M
Single-cell and imaging data integration software to spatially resolve the tumor microenvironmentU01CA253403 · NCI · JOHNS HOPKINS UNIVERSITY · PI FERTIG, ELANA · 2020 to 2022
$1.2M
Organ Specific ProjectU54AR081774 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI REDDY, SASHANK K, WIRTZ, DENIS · 2022 to 2023
$1.1M
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic CancerK08CA248624 · NCI · JOHNS HOPKINS UNIVERSITY · PI ZAIDI, NEEHA · 2021 to 2025
$1.1M
NCI NIH HHS F31 CA284525NCI NIH HHS K08 CA248624NCI NIH HHS P01 CA247886NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA197296NCI NIH HHS R37 CA292056NCI NIH HHS U01 CA253403NCI NIH HHS U54 CA143868NCI NIH HHS U54 CA268083NCI NIH HHS U54 CA274371NIAMS NIH HHS U54 AR081774NIGMS NIH HHS T32 GM007814NIH HHS S10 OD034407
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a poor survival rate due to late detection. PDAC arises from precursor microscopic lesions, termed pancreatic intraepithelial neoplasia (PanIN), that develop at least a decade before overt disease; this provides an opportunity to intercept PanIN-to-PDAC progression. However, immune interception strategies require full understanding of PanIN and PDAC cellular architecture. Surgical specimens containing PanIN and PDAC lesions from a unique cohort of 5 treatment-naive patients with PDAC were surveyed using spatial omics (proteomic and transcriptomic). Findings were corroborated by spatial proteomics of PanIN and PDAC from tamoxifen-inducible KPC mice. We uncovered the organization of lymphoid cells into tertiary lymphoid structures (TLSs) adjacent to PanIN lesions. These TLSs lacked CD21+CD23+ B cells compared with more mature TLSs near the PDAC border. PanINs harbored mostly CD4+ T cells, with fewer Tregs and exhausted T cells than PDAC. Peritumoral space was enriched with naive CD4+ and central memory T cells. These observations highlight the opportunity to modulate the immune microenvironment in PanINs before immune exclusion and immunosuppression emerge during progression into PDAC.

Indexed as

Carcinoma in SituCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAnimalsDisease ProgressionFemaleHumansMaleMiceMiddle AgedProteomicsTertiary Lymphoid StructuresTranscriptomeTumor MicroenvironmentAdaptive immunityCancer immunotherapyGastric cancerImmunologyInflammationOncology

Identifiers

PMID40569674
PMCPMC12333942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.